AstraZeneca (LON:AZN) has been given a GBX 6,100 ($79.71) target price by analysts at Jefferies Financial Group in a report issued on Thursday. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price would suggest a potential downside of 2.26% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. lifted their target price on shares of AstraZeneca from GBX 6,900 ($90.16) to GBX 7,100 ($92.77) and gave the stock an “overweight” rating in a research report on Wednesday, January 2nd. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, February 5th. Shore Capital reissued a “hold” rating on shares of AstraZeneca in a research report on Tuesday, November 6th. Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the company a “sell” rating in a research report on Friday, November 16th. Finally, Credit Suisse Group set a GBX 6,350 ($82.97) price objective on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, December 7th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca presently has a consensus rating of “Buy” and an average target price of GBX 6,222.20 ($81.30).

LON:AZN opened at GBX 6,241 ($81.55) on Thursday. AstraZeneca has a 12 month low of GBX 4,260 ($55.66) and a 12 month high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Analyzing a company’s cash flow statement

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.